Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.

The University of Dallas has become the first school in the nation to award academic credit through the Classical ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28 ...

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing ...

When filmmaker Imtiaz Ali creates a world on screen, every detail matters. From the emotions of his characters to the spaces ...

Sjögren’s disease (SjD) is a chronic, multisystem autoimmune disorder characterised by lymphocytic infiltration of exocrine ...

When the publisher, Hoxton Mini Press, asked if I wanted to write a book on garden visits, I didn’t hesitate for long. After ...

Sanofi (NASDAQ:SNY) said on Wednesday that it has decided to discontinue the phase 3 MOBILIZE trial evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who ...

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today announced that the riliprubart MOBILIZE phase ...

The complement system has an important role in physiological bone healing, as studied mainly in animal models and local bone tissues. However, the role of the complement system in human fractures, ...

Cash and operating runway: Cash, cash equivalents and short-term investments were $225.0 million as of March 31, 2026. Based on focused investments in its lead late-stage programs, Annexon expects to ...